Nalaganje...
Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
BACKGROUND: Ixazomib-revlimid-dexamethason showed significant activity in relapsed/refractory multiple myeloma (RRMM). Here, we evaluate ixazomib in combination with thalidomide and dexamethasone for induction treatment followed by ixazomib maintenance therapy in RRMM patients. METHODS: Ninety patie...
Shranjeno v:
| izdano v: | Br J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group UK
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6889132/ https://ncbi.nlm.nih.gov/pubmed/31558804 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0581-8 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|